Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

NCT03600233 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor
Gastro-enteropancreatic Neuroendocrine Tumor
Lung Neuroendocrine Neoplasm
Neuroendocrine Carcinoma

Interventions

DRUG: CVM-1118

Sponsor

TaiRx, Inc.